28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.
To determine downstream revenue of neurologists compared with nonneurologists after incident diagnostic visits by analysis of Medicare claims. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The objective of this study was to investigate the cost of care for patients with a primary diagnosis of dementia in Swiss hospitals under the new TARPSY reimbursement system. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Conducting high-quality health technology assessments requires high-quality evidence. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Protein folding is a critical process that determines the functional state of proteins. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
This manuscript examines the research questions being addressed in prevention research by characterizing the distribution and trends of study designs included in primary and secondary prevention research supported by the National Institutes of Health through grants and cooperative agreements, together with the types of prevention research, populations, rationales, exposures, and outcomes associated with each type of design. 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
We study the impact of grocery-store density on the food waste generated at stores and by households. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This Medical News article discusses care denials under Medicare Advantage plans and efforts to streamline the prior authorization process. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
System affiliation is associated with less restrictive PA policies in MA, highlighting organizational structure as an important dimension of utilization management. 3 key findings →
Participants: 6,480 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Little is known about the extent of prior authorization requirements in otolaryngology. 5 key findings →
Participants: 34 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Compared with “well-nourished,” “malnourished” PWD had 3-4 times the hazard of severe dementia [hazard ratio (HR), 4.31; P =0.014] and death (HR, 3.04; P <0.001). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Acute injections of Aβ oligomers had no effect on p-tau epitopes but did result in elevation of phosphorylated/activated GSK3 (pGSK3). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We evaluated the brain metabolic correlates of main indexes of a widely used word list learning test, the Rey Auditory Verbal Memory Test (RAVLT), in a group of elderly subjects with memory complaints. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This report summarizes the consensus recommendations of a panel of neuropathologists from the United States and Europe to improve the postmortem diagnostic criteria for Alzheimer's disease.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A standardized, semi-structured interview for examining and recording the mental state in elderly subjects is described.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Reviewing the research presented in this article, it is evident that from an epidemiological perspective, it is important to evaluate the extent to which findings of sex and gender differences in Alzheimer's dementia (AD) are due to differences in longevity, survival bias, and comorbidities. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
We found that both Adu and SUS reduced the total plaque area in the hippocampus to a similar degree, with no additive effect in the combination treatment (SUS+Adu). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Dementia with Lewy bodies (DLB) is the second commonest cause of neurodegenerative dementia in older people. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Despite the use of highly active antiretroviral therapy (HAART), neuronal cell death remains a problem that is frequently found in the brains of HIV-1-infected patients. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Parkinson's disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are adult onset neurodegenerative disorders characterised by prominent intracellular α-synuclein aggregates (α-synucleinopathies). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
These data reveal a link between reduced glucocerebrosidase and the development of α-synucleinopathy and pathophysiological abnormalities in mice, and support the development of GCase therapeutics to reduce α-synucleinopathy in PD and related disorders. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Overexpression of apoE isoforms induces differential effects in the apoE4-TR background: apoE4 decreases apoE lipidation and enhances Aβ accumulation, whereas apoE2 has the opposite effects. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Selective loss of neurons, abnormal protein deposition and neuroinflammation are the common pathological features of neurodegenerative diseases, and these features are closely related to one another. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Amyloid-beta peptide is elevated in the brains of patients with Alzheimer disease and is believed to be causative in the disease process. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Acetylcholine (ACh) has a crucial role in the peripheral and central nervous systems. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Synaptic loss is the best pathological correlate of the cognitive decline in Alzheimer's disease; however, the molecular mechanisms underlying synaptic failure are unknown. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →